Guardant Health, Inc. (GH)
After hours:
| Previous close | 26.11 |
| Open | 26.17 |
| Bid | 25.96 x 1200 |
| Ask | 26.00 x 800 |
| Day's range | 25.41 - 26.38 |
| 52-week range | 20.67 - 62.75 |
| Volume | |
| Avg. volume | 1,517,414 |
| Market cap | 3.052B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.67 |
| Earnings date | 01 Nov 2023 - 06 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 55.56 |
Simply Wall St.Insider Buyers At Guardant Health Sitting On US$653k Profit
Insiders who bought Guardant Health, Inc. ( NASDAQ:GH ) stock lover the last 12 months are probably not as affected by...
Business WireGuardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
PALO ALTO, Calif., September 06, 2023--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It
Business WireGuardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
PALO ALTO, Calif., September 05, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic to select patients with unresectable (inoperable) advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations that has progressed after chemotherapy for treatment with ENHERTU® (trastuzumab deruxtecan). ENHER
